Oxidized lipoproteins may play a role in neuronal cell death in alzheimer disease

Molecular and Chemical Neuropathology

Volumn 33, Issue 2, 1998, Pages 139-148

  Draczynska Lusiak, Bozena ^a   Doung, Ann ^a   Sun, Albert Y ^a  

^a University of Missouri   (United States)

Author keywords

Alzheimer disease; Apo E; Lipid peroxides; Oxidized low density lipoprotein; PC12 cells; Very low density lipoprotein

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; LIPID PEROXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CYTOTOXICITY; LIPID OXIDATION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0031947574     PISSN: 10447393     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02870187     Document Type: Article

References (30)

1. Arichi H., Kimura Y., Okuda H., Baba K., Kozawa M., and Arichi S. (1982) Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem. Pharm. Bull. 30, 1766-1770.
2. Borovic S., Zarkovic N., Wildburger R., Tatzber F., and Jurin M. (1995) Post-traumatic differences in the titer of autoantibodies against oxidized low density lipoproteins (OLDL) in the sera of patients with bone fracture and traumatic brain injury. Periodicum Biol. 97, 209-293.
3. Chanvitayapongs S., Draczynska-Lusiak B., and Sun A. Y. (1997) Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. NeuroReport 8, 1499-1502.
4. Cheng Y., Chen M., James-Kracke M., Wixom P., and Sun A. Y. (1996) Enhanced lipid peroxidation by extracellular ATP in PC12 cells. Neurochem. Res. 21, 27-33.
5. Chisolm G. M., Ma G., Irwin K. C., Martin L. L., Gundeson K. G., Linberg L. F., et al. (1994) 7β-Hydroxy-peroxycholest-5-en-3β-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc. Natl. Acad. Sci. USA 91, 11,452-11,456.
6. Chung M. I., Teng C. M., Cheng K. L., Ko F. N., and Lin C. N. (1992) An anti-platelet principle of veratrum formosanum. Planta Med. 58, 274-276.
7. Dehouck B., Dehouck M., Fruchart J., and Cecchelli R. (1994) Upregulation of the low density lipoprotein's receptor at the blood-brain barrier: Intercommunications between brain capillary endothelial cells and astrocytes. J. Cell Biol. 126, 465-473.
8. Dehouck B., Fenart L., Dehouck M., Pierce A., Tarpier G., and Cecchelli R. (1997) A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877-889.
9. Escargueil-Blanc I., Salvayre R., and Negre-Salvayre A. (1994) Necrosis and apoptosis induced by oxidized low density lipoproteins occurs through two calcium-dependent pathways in lymphoblastoid cells. FASEB J. 8, 1075-1080.
10. Esterbauer H., Gebicki J., Puhl H., and Jürgens G. (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical. Biol. Med. 13, 341-390.
11. Frankel E. N., Waterhouse A. L., and Kinsella J. E. (1993) Inhibition of human low density lipoprotein oxidation by resveratrol. Lancet 341, 1103, 1104.
12. Goldstein J. L., Ho Y. K., Basu S. K., and Brown M. S. (1979) Binding site on macrophages that mediates uptake and degradation of acetylated LDL, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 96, 333-337.
13. Goldstein J. L., Basu S. K., and Brown M. S. (1983) Receptor mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98, 241-261.
14. Hatch F. T. and Lees R. S. (1968) Practical methods for plasma lipoproteins analysis. Adv. Lipid Res. 6, 1-68.
15. Hessler J. R., Robertson A. L., and Chisolm G. M. (1979) LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32, 213-229.
16. Jang M., Cai L., Udeani G. O., Slowing K. V., Thomas C. F., Bescher C. W. W., et al. (1997) Cancer preventive activity of resveratrol, a natural product derived from grape. Science 275, 218-220.
17. Kim D. H., Iijima H., Goto K., Sakai J., Ishii H., Kim H. J., et al. (1996) Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271, 8373-8380.
18. Lyras L., Cairns N. J., Jenner A., Jenner P., and Halliwell B. (1997) An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68, 2061-2069.
19. Osman I., Gaillard O., Meiller D., Bordas-Fonfrede M., Gervais A., Schuller E., et al. (1995) A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid: application to multiple sclerosis and other neurological diseases. Eur. J. Clin. Chem. Clin. Biochem. 33, 53-58.
20. Pitas R. E., Boyles J. K., Lee S. H., Hui D., and Weisgraber K. H. (1987) Lipoproteins and their receptors in the central nervous system. J. Biol. Chem. 262, 14,352-14,360.
21. Poirier J., Hess M., May P. C., and Finch C. E. (1991) Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol. Brain Res. 11, 97-106.
22. Poirier J., Baccichet A., Dea D., and Gauthier S. (1993) Cholesterol synthesis and lipoprotein reuptake during synaptic remodeling in hippocampus in adult rats. Neuroscience 55, 81-90.
23. Rebeck G. N., Reiter J. S., Strickland D. K., and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interaction. Neuron 11, 575-580.
24. Roses A. D. (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-100.
25. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. J., Pericak-Vance M. A., Joo S. H., et al. (1993) Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472.
26. Sayre L. M., Zalasko D. A., Harris P. L. R., Perry G., Salomon R. G., and Smith M. A. (1997) 4-hydroxynonenal-derived advanced lipid peroxidation end product are increased in Alzheimer's disease. J. Neurochem. 68, 2092-2097.
27. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., and Witzrum J. L. (1989) Beyond cholesterol: modifications of low density lipoprotein that increases its atherogenecity. N. Engl. J. Med. 320, 915-924.
28. Steinbrecher U. P., Witzrum J. L., Parthasarathy S., and Steinberg D. (1987) Decrease in reactive amino group during oxidation on endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 1, 135-143.
29. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., et al. (1993a) Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
30. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. N., Salvesen G. S., Pericak-Vance M., et al. (1993b) Binding of human apolipoprotein E to synthetic amyloid beta peptides: isoform specific effects and implication for late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90, 8098-8102.